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Edited by Georg SchulzAbstract
The gluconeogenic enzyme fructose-1,6-bisphosphatase has been proposed as a potential drug target against
Leishmania parasites that cause up to 20,000–30,000 deaths annually. A comparison of three crystal structures of
Leishmaniamajor fructose-1,6-bisphosphatase (LmFBPase) along with enzyme kinetic data show howAMPacts
as an allosteric inhibitor and provides insight into itsmetal-dependent reactionmechanism. The crystal structure of
the apoenzyme form of LmFBPase is a homotetramer in which the dimer of dimers adopts a planar conformation
with disordered “dynamic loops”. The structure of LmFBPase, complexed with manganese and its catalytic
product phosphate, shows the dynamic loops locked into the active sites. A third crystal structure of LmFBPase
complexed with its allosteric inhibitor AMP shows an inactive form of the tetramer, in which the dimer pairs are
rotated by 18° relative to each other. The three structures suggest an allosteric mechanism in which AMP binding
triggers a rearrangement of hydrogen bonds across the large and small interfaces. Retraction of the “effector loop”
required for AMPbinding releases the side chain ofHis23 from thedimer–dimer interface. This is coupledwith a flip
of the side chain of Arg48 which ties down the key catalytic dynamic loop in a disengaged conformation and also
locks the tetramer in an inactive rotated T-state. The structure of the effector site of LmFBPase shows different
structural features compared with human FBPases, thereby offering a potential and species-specific drug target.
Crown Copyright © 2017 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Trypanosomatids of the genera Trypanosoma and
Leishmania are parasitic protists that cause a spectrum
of diseases in humans andmany animals. In particular,
Leishmania species are responsible for cutaneous
diseases (ulcers and destructive lesions) and for a
visceral form involving an infection of the liver and
spleen that is usually fatal if untreated. The World
Health Organization estimates that approximately
700,000 to 1 million new cases of leishmaniases
occur annually and are prevalent in 98 countries on five
continents [1]. Of these cases, 300,000 are the visceral
form also known as kala-azar, and estimates of deaths
from this disease range from 20,000 to 30,000 people
annually [2]. Leishmania exist in two main morpholog-ight © 2017 Published by Elsevier Ltd. Th
enses/by/4.0/).
: M. Yuan, et al., Structures of Leishmania Fr
ric Inhibition, J. Mol. Biol. (2017), http://dx.doi.ically distinct forms: motile flagellated promastigotes,
which occur in the sand-fly vector and are injected into
human skin. After phagocytosis by macrophages, they
develop into non-flagellated amastigotes in the macro-
phage's phagolysosome where they proliferate.
Anti-leishmanial vaccines are not currently available,
and treatments rely on chemotherapy but are charac-
terized by low efficacy, toxicity, and/or widespread
resistance [3–5].
The gluconeogenic pathway of Leishmania con-
verts metabolites into sugar phosphates to be used in
the pentose phosphate pathway for synthesis of
mannogen and glycoconjugates, which are essential
for amastigote replication and virulence [6].
Fructose-1,6-bisphosphatase (FBPase) is a gluconeo-
genic enzyme that catalyzes the transformation of
is is an open access article under the CC BY license (http://
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2 Leishmania Fructose-1,6-Bisphosphatasefructose 1,6-bisphosphate (F16BP) to fructose
6-phosphate (F6P) and phosphate. It is found in
glycosomes, organelles related to peroxisomes, and
found only in protists of the groups Kinetoplastea and
Diplonemida, such as the genera Leishmania and
Trypanosoma [7]. Leishmania FBPase (LmFBPase)--
null promastigotes were shown to be internalized by
macrophages and to differentiate into amastigotes, but
were unable to replicate in themacrophage phagolyso-
some and failed to generate lesions in mice [8].
Mammalian FBPases (especially pig and human
FBPases) are enzymologically and structurally well
characterized [9,10]. The enzymes occur as very
similar liver and muscle isoforms and are homotetra-
mers assembled as a pair of dimers. In R-state
structures of the liver isoform, the tetramer adopts a
planar conformation of the dimers. However, the
recently reported R-state structure of muscle FBPase
adopts a conformation in which the pairs of dimers are
perpendicular to each other [10]. AMP is an allosteric
inhibitor of both liver and muscle forms that binds at a
site 30 Å from the active site [11]. Binding of AMP
induces a conformational change of the tetramer from
either a planar or a perpendicular R-state to a twisted
T-state [10,12,13]. Despite sharing a conserved
sequence (77% identity), the muscle FBPase is
100-fold more sensitive to AMP inhibition than its liver
counterpart and is inhibited by calcium ions [14]. The
allosteric AMPbinding site in human liver FBPase is an
antidiabetic drug target, and structure-based design
approaches have been used to develop small-mole-
cule inhibitors which are currently being evaluated in
the clinic [15–18].
TheR-state andT-state structurespresentedhere for
LmFBPase are similar to the canonical structures of
human liverFBPase,with theR-state tetrameradopting
a relatively planar conformation and the inhibited
AMP-bound T-state adopting a twisted conformation.
However, the biochemical and structural data on
LmFBPase show differences in the allosteric mecha-
nism of AMP inhibition compared with the human
enzymes. Given the importance of LmFBPase to
proliferation of the human pathogenic form of the
parasite and formation of lesions, these structural and
mechanistic differences suggest that the LmFBPase
allosteric AMP-binding pocket could provide a potential
new species-specific target for anti-leishmaniasis
drugs.Results and Discussion
Sequence alignment of FBPases from different
organisms
Sequence alignment between LmFBPase and
mammalian FBPases (Fig. 1, Fig. S1, and Table S1)
shows that the enzymes are moderately conserved,Please cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.despite the long evolutionary divergence between
trypanosomatids and mammals. Moreover,
LmFBPase is essentially equidistant from human
liver FBPase (hlFBPase) and human muscle FBPase
(hmFBPase), with 44% and 41% overall sequence
identity, respectively. The active sites from LmFBPase
and mammalian FBPases are very well conserved,
with 13out of 14 residues being identical, except for the
replacement of Tyr221 by Asn in LmFBPase and
Escherichia coli FBPase (all residues are numbered
according to LmFBPase in this paper, unless stated
otherwise). The dynamic loop (residues 52–71), which
has been shown to be catalytically important in
mammalian FBPases, is in a similar position in
LmFBPasebut shows functionally important sequence
differences and has two insertions (Tyr57 and Gln61)
compared with mammalian and bacterial sequences
(Fig. S1). The AMP binding sites of LmFBPase and
mammalian FBPases are relatively poorly conserved.
Intriguingly, the basic residue Lys112, which was
predicted to be one of three conserved residues
required for the inhibitory effect of AMP [20], is
replaced by an acidic residue Asp112.
Enzymatic characterization of LmFBPase
A plate-based enzymatic activity assay has been
developed for trypanosomatid FBPases bymonitoring
the formation of NADPH produced via the coupling
enzymes phosphoglucose isomerase (PGI) and
glucose-6-phosphate dehydrogenase (G6PDH). The
activity assays show that the substrate F16BP binds
to the enzyme with positive cooperativity (nH = 1.8).
TheK0.5 value of 19.8 μM (Fig. 2) is similar to that ofE.
coli FBPase isotype I, but considerably larger than
those of the mammalian FBPases, which have Km
values of around 1 to 2 μM (Table 1). The higher Km
for LmFBPase may be explained by a sequence
difference at the active site (Fig. S1), with Tyr221
replaced by Asn221 resulting in the loss of a direct
hydrogen bond with the F16BP substrate (discussed
later in conjunction with the X-ray results).
Magnesium is required for catalytic activity of
LmFBPase, and a Michaelis–Menten plot of activity
versus magnesium concentration gives a Km value of
1.2 mM (Fig. S2a). Manganese, however, showed an
inhibitory effect on LmFBPase activity with a Ki of
44.3 μM (Fig. S2b). No data for manganese levels in
leishmanial promastigotes or amastigotes have been
determined; however, measurements on Trypano-
soma brucei [23] estimated levels of ~1 μM manga-
nese in the cytosol. It is unlikely, therefore, that
manganese inhibition of LmFBPase is physiologically
relevant. Calcium also inhibits LmFBPase activity, with
an inhibitor constant similar to that of manganese (Fig.
S2b). Both mammalian FBPase isoforms are also
inhibited by calcium but with amuch stronger inhibition
against muscle FBPase (Ki = 1 μM) than against liver
FBPase (Ki N 1 mM) [14].uctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
Fig. 1. Overall structure of a monomer of LmFBPase. The helices, strands, and loop regions are labeled and are shown
in red, yellow, and green cartoon ribbons, respectively. These secondary structure elements are also indicated in the
alignment by the same colors. The positions of both ends of the “dynamic loop” (residues 52–71) are shown with purple
arrows in the figure, whereas its sequence is highlighted by purple background in the alignment. The position of the active
site is shown with an orange circle in the structure, whereas its residue codes are highlighted by orange background in the
alignment. Similarly, the effector site is shown in cyan. Sequence alignment between LmFBPase and human was
performed with MUSCLE [19]. The terminal residues 1–7 and 338–350 as well as the C-terminal His-tag were not built into
the structure models due to the lack of electron density.
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Fig. 2. Kinetic characterization of LmFBPase. (a) Determination of the values of kinetic parameters of LmFBPase with
its substrate F16BP. (b) The inhibitory effect of AMP on LmFBPase. (c) The inhibitory effect of F26BP on LmFBPase
activity. (d) Kinetic characterization of LmFBPase in the presence of different concentrations of F26BP. (e) The effect of
AMP titration on the specific activity of LmFBPase in the presence of different concentrations of F26BP. (f) The Ki of AMP
for LmFBPase decreases when higher concentrations of F26BP are present.
4 Leishmania Fructose-1,6-BisphosphataseInhibitory effects of AMP
AMP binds to an effector site about 30 Å distant
from the active site and its allosteric inhibition is well
characterized in mammalian FBPases [20]. Se-
quence alignment of mammalian and LmFBPase
shows that the residues involved in AMP binding arePlease cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.poorly conserved (Fig. 1), with only three identical
out of eight amino acids. Gao et al. [20] showed that
in mammalian FBPases, AMP inhibition requires
serine or threonine as position 31 (position 29 in
LmFBPase), lysine or arginine at position 112, and
tyrosine at position 113. LmFBPase retains Thr29
and Tyr113, but has an aspartic acid at position 112uctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
Table 1. Kinetic parameters for Leishmania major, mammalian and bacterial FBPases
Kcat (s
−1) K0.5 (μM) Kcat/K0.5 (M
−1 s−1) nH [Mg
2+] Ka[Mg
2+] (mM) Ki [AMP] (μM) nH [AMP] Reference
L. major 8.0 19.8 4.0 × 105 1.8 1.2 63.8 1.4 This study
Human isotype I 20.8 2.1 9.9 × 106 1.8 0.2 4.4 2.1 Rakus et al. [11]
Human isotype II 23.4 1.3 1.8 × 107 1.9 0.2 0.1 1.8 Rakus et al. [11]
Pig isotype I 20.0 1.2 1.7 × 107 1.7 0.8 0.6 2.2 Iancu et al. [21]
E. coli isotype I 14.6 15.4 9.5 × 105 NDa 0.6 2.7 1.1 Kelley-Loughnane
et al. [22]
a ND, not determined.
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Fig. 3. Melting temperatures (Tm) of LmFBPase in the
absence and presence of ligands (2 mM) and/or Mn2+
(10 mM). The shaded bars correspond to the presence of
Mn2+. The thermostability of LmFBPase and the effects of
ligands and/or Mn2+ were determined with a thermal shift
assay (see Materials and Methods for details).
5Leishmania Fructose-1,6-Bisphosphataseinstead of a basic residue. The lack of sequence
conservation at the effector site explains the weaker
binding of AMP to LmFBPase than to mammalian
FBPases (Ki = 63.8 μM compared with 0.1–4 μM).
The allosteric inhibitory effect of AMP on LmFBPase
is shown in Fig. 2b, and the determined Ki value of
63.8 μM is in the likely physiological range of cellular
AMP concentration in trypanosomatids (estimated to
be between 250 and 2000 μM in different growth
phases of T. brucei) [24]. This suggests that the
FBPase activity and thus gluconeogenesis is under
AMP regulation in trypanosomatids.
Thesynergistic inhibitory effect of F26BPwithAMP
Fructose 2,6-bisphosphate (F26BP) binds at the
active site, and acts as a competitive inhibitor of both
liver and muscle isoforms of mammalian FBPases
with inhibition constants of 0.5 and 0.2 μM, respec-
tively [25–29]. In this study, F26BP also shows an
inhibitory effect on LmFBPase, with a Ki of 1.9 μM
(Fig. 2c). A kinetic characterization of LmFBPase in
the presence of different F26BP concentrations
demonstrated that F26BP reduces the substrate
binding affinity without altering the maximum activity
(Fig. 2d), confirming that F26BP is a competitive
inhibitor of LmFBPase activity.
AMP inhibition of mammalian liver FBPase is
enhanced up to 10-fold in the presence of F26BP, in
an effect termed AMP/F26BP synergism [25,26].
Here we show AMP/F26BP has a similar synergistic
effect on LmFBPase. A Ki[AMP]-versus-[F26BP]
graph (Fig. 2f) clearly shows the trend that the AMP
inhibitory effect is F26BP dependent. In the pres-
ence of F26BP, the Ki for the AMP falls by up to
13-fold.
Ligands greatly affect the thermostability of
LmFBPase
The velocities of LmFBPase unfolding in the
absence and presence of different ligands and/or
Mn2+ as a function of increasing temperature were
determined with a thermal denaturation assay
(TDA). The results (Fig. 3) show that in the absence
of ligands, the melting temperature (defined as thePlease cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.temperature midpoint for the protein unfolding
transition [30]) of LmFBPase was 56.5 °C. Thermo-
stability in the presence of the substrate F16BP was
increased strikingly for LmFBPase with a ΔTm of
about 8 °C. In contrast, the inhibitor AMP caused
only a modest change in the stability of the protein.
Furthermore, the stabilization effect of F16BP was
not eliminated by AMP, but the stabilizing effects
were additive. This result implies that AMP inhibits
the catalytic activity of LmFBPase without eliminat-
ing the substrate binding. The catalytic product F6P
also showed a stabilization effect on LmFBPase, but
not as significant as the substrate F16BP. This result
suggests that the 1′-phospho group of F16BP may
also play an important role in the stabilization of
LmFBPase.
The thermostability of LmFBPase was increased by
more than 9 °C in the presence of Mn2+, similar to the
increase from the binding of F16BP. The thermosta-
bility of LmFBPase plus Mn2+ was also determined in
the presenceof natural ligands. F16BP in the presence
of Mn2+ showed a further stabilization of LmFBPase
by increasing the Tm by about 8 °C, whereas AMP
caused only a modest thermostability change. Theuctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
Fig. 4. Overall structures of LmFBPase. The large interface [between the Chain 1/Chain 4 (C1C4) dimer and the C2C3
dimer] and small interface (between the C1C2 dimer and the C3C4 dimer) are shown in dashed lines in each
homotetramer. Positions of active sites and effector sites are highlighted by arrows and circles in the first figure, where
secondary structures are shown in different colors in Chain 1 (helices, β-strands and loop regions in red, yellow, and green,
respectively). Bound ligands are shown as spheres. The dynamic loops (residues 52–71) are indicated in purple.
Schematic models (adapted from diagrams in Gidh-Jain et al. [12]) are shown in the bottom right of each panel. (a)
LmFBPase structure in an unligated state. (b) Structure of LmFBPase–phosphate–Mn2+ complex. (c) The structure of
LmFBPase–AMP–F6P complex is in an allosterically inhibited conformation.
6 Leishmania Fructose-1,6-Bisphosphataselargest shift in thermostability of more than 20 °C
occurred in the presence of Mn2+, F16BP plus AMP.
Due to the strong stabilization effect of Mn2+, it was
used as a “silver bullet” to crystallize one of the
LmFBPase crystal forms.
Apoenzyme structure of LmFBPase
Three crystal structures of LmFBPase have been
determined: an apoenzyme structure that is in an
unligated state, a structure bound with its catalytic
product, and a structure in its allosterically inhibited
form (Fig. 4). All three crystallize in space group
P212121 with one tetramer per asymmetric unit. The
terminal residues 1–7 and 336–350 as well as the
C-terminal His-tag were not built into the structure
models due to the lack of interpretable electron density.
The crystal structure of LmFBPase apoenzymewas
solved to 2.41-Å resolution using molecular replace-
ment with reference to a monomer of a pig liver
FBPase structure (PDB code: 5FBP) [31]. The
monomer core structure of LmFBPase has an α/β/α/
β/α “club sandwich” topology, with twomixed β-sheets
flanked by α-helices on both sides (Figs. 1 and 4a).
The active site is located at the end of the B9 strand
and adjacent to the N-terminus of the H9 helix. The
effector site is located between the termini of helices
H1 and H2, and incorporates the seven-residue
effector loop (residues 20–26) joining these two
helices. The hanging drop in which the apoenzyme
structure was crystallized contained F16BP and
Mg2+; however, no ligands are observed in the
structure. The topology of the apoenzyme tetramer
is planar (Fig. 4a), but is rotated in the presence of the
allosteric inhibitor AMP (discussed below).Please cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.The homotetramer ofLmFBPase is formed from two
types of dimer as shown by the schematic models in
Fig. 4. The Chain1Chain2 dimer is on the top and the
Chain3Chain4 dimer on the bottom, and form the
"small interface" (2507 A2) between these dimers.
Similarly the C2C3 dimer is on the left and the C1C4
dimer on the right, and form the "large interface" (3850
A2) between these dimers. The active site is located
close to the large interface and comprises residues
from adjacent monomers. Small interface interactions
mainly involve helices H1, H2, and H3 and strands B6
and B7 (Fig. 1). In the apoenzyme structure, the
effector loop “20QPPHSRG26” between helices H1
and H2 adopts a conformation that strengthens the
interactions across the small interface. Movement of
this loop is critical for the allosteric inhibition mecha-
nism triggered by AMP binding.
Intriguingly, not only interactions across both the
small and the large interfaces, but also interactions
between diagonal chains are formed. Two indepen-
dent, but identical symmetry-related clusters of
hydrogen bonds, each lying across the 2-fold sym-
metry axis of the tetramer, are formed by Asn195 and
Arg48 (Fig. 5d). The rearrangement of these eight
hydrogen bonds that stabilize the core of the homo-
tetramer in the planar R-state regulates the R to T
switching mechanism (Fig. 5d, discussed below).
Crystal structure of LmFBPase in complex with
inorganic phosphate and metal ions
Manganese was demonstrated by TDA measure-
ments to be a strong stabilizer of LmFBPase (Fig. 3)
and was used as an additive to crystallize LmFBPase.
Co-crystallization of LmFBPase with Mn2+ and theuctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
Fig. 5. Crystal structures show allosteric effects of AMP on LmFBPase. (a), Schematic representations of the
LmFBPase structures. Each trapezoid block represents a chain in this homotetramer (adapted from diagrams in Gidh-Jain
et al. [12]). Black blocks show the planar topology, while the purple, rotated blocks represent the rotated state. AMP
binding sites are indicated with purple ellipses. Positions corresponding to panels b, c, and d are also indicated with black
dashed rectangles. (b) Comparison of the AMP binding sites in the planar state structure (green) and the rotated state
structure (purple). The planar state and the rotated state structures are superposed on Chain 1 (C1). The blue dashed line
shows the short interface. (c) Comparison of the short interfaces of the planar state (left) and rotated state (right) structures.
C1 chains are shown in green and purple for the planar and rotated state structures, respectively. C4 chains are shown in
gray in each figure. The blue dashed line shows the short interface. (d) Interactions between all four chains in the central
region of LmFBPase. (Left) Hydrogen bonds in the central region of the planar state of LmFBPase involve all four chains.
These form two independent, but identical symmetry-related hydrogen bond clusters. Chains 1, 2, 3, and 4 are represented
in green, cyan, magenta, and yellow, respectively. For the convenience of comparison, the relative position of the dynamic
loop of rotated-state LmFBPase is shown in transparent orange. (Right) The same region but in the rotated inactive T-state
has a different network of hydrogen bonds because the side chain of Arg48 has switched to a different position upon AMP
binding. Chains 1, 2, 3, and 4 are represented in orange, cyan, magenta, and yellow, respectively. For the convenience of
comparison, the relative position of the dynamic loop of planar-state LmFBPase is shown in transparent green.
7Leishmania Fructose-1,6-Bisphosphatasesubstrate F16BP resulted in crystals in which a
catalytic product Pi and manganese atoms were
found in each active site (shown in Fig. 6b, d). The
overall conformation is very similar to the apoenzyme
structure, with anRMSDvalue of only 1.0 Å (based on
Cα atoms). This structure also adopts a planar
topology, which has no significant rotational move-
ment of domains as analyzed by Dyndom [32]. The
dynamic loop (residues 52–71) was found to adopt an
engaged conformation (Fig. 4b), in contrast to the
apoenzyme structure where the dynamic loop was
found to be disordered in two of the chains. The
dynamic loop is inserted into the active site, showing
the involvement of the catalytically critical Asp68 that
interacts with a cation at site III which binds to the
catalytic product Pi in the active site (Fig. 6d).
Crystal structure of LmFBPase in complex with
AMP
The LmFBPase tetramer co-crystallized with the
substrate F16BP in the presence of the allosteric
inhibitor AMP and manganese adopts a twisted
conformation. The catalytic product F6P was found
in each of the active sites of the four subunits, andPlease cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.AMP was located in each of the four effector sites at
approximately 32 Åaway from theactive sites (Fig. 4c).
Although it did not significantly change the monomer
conformation in comparison with the apoenzyme
structure (RMSD of 1.0 Å based on Cα atoms), the
overall tetramer structure had an RMSD of 3.8 Å (Fig.
S3). The difference was a result of AMP binding which
induced an 18° rotation, shearing the small interface
and rotating the C1–C2 dimer relative to the C3–C4
dimer to yield a “rotated structure”.
As a result of this rotation, the dynamic loop
(residues 52–71) is pulled out from the active site in a
canonical “disengaged conformation” [33], which is
stabilized by the diagonal subunit. Removal of key
residues (especially Asp68) of the dynamic loop
from the active site deactivates LmFBPase. The
“disengaged-conformation” (in which most of the loop
is disordered in the AMP-bound structure) is prevented
from adopting an active conformation by the strong
hydrogen bonded network around Arg48 which hydro-
gen bonds to the dynamic loop (residue 52) (Fig. 5d)
and pointing the remainder of the loop out into solvent.
The conformations of the dynamic loop identified in the
three different crystal structures show the key catalytic
role the loopplays in theallosteric FBPasemechanism:uctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
Fig. 6. Comparison of the active sites of pig liver FBPase (panels a and c, blue; generated from the work by Choe et al.
[33]; PDB code: 1EYI] and L. major FBPase (panels b and d, green; generated from this study). F6P molecules are shown
in magenta. Arginines from adjacent chains are shown in gray. The electron density of F6P in panel B (colored in cyan) is
from Fo − Fc maps contoured at the 3.0σ level. Electron density at the metal sites in panel d (gray mesh) is from 2Fo − Fc
maps contoured at the 3.5σ level.
8 Leishmania Fructose-1,6-Bisphosphatasethe hydrogen bond interactions between Arg48 and
the backbone carbonyl oxygen atoms of Met51 and
Lys52 tie down the disordered loop in an inactive
conformation (Fig. 5d). There is also a strong salt
bridge between Arg48 and Asp193 from Chain 2
across the large interface. In the R-state, the Arg48
side chain rotates 180° round the Χ11 to release the
disordered loop and help lock the tetramer in a planar
conformation by forming a hydrogen bond to Asn195
(Chain 4) across the short interface (Fig. 5d).
As found in both mammalian and Leishmania
FBPases, the formation of the complete active site is
facilitated by Arg247 from the adjacent subunit across
the large interface, which formsan ionic interactionwith
the 6′-phospho group of the catalytic product F6P (Fig.
6a, b). This interaction also demonstrates that the
tetrameric form of LmFBPase is necessary for cataly-
sis. The sequence alignment (Fig. 1) shows that the
active sites among Leishmania and mammalian
FBPases are conserved, except for a one-residue
difference—the tyrosine that is responsible for bindingPlease cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.to the 6′-phospho group of the catalytic substrate/
product inmammalian FBPases is replaced byAsn221
in LmFBPase. The shorter side chain of Asn221 may
explain the weaker substrate binding affinity of
LmFBPase compared with mammalian FBPases
affinity as Asn221 cannot make a direct hydrogen
bondwith theF16BPsubstrate (Fig. 6). Similar catalytic
properties of E. coli FBPase, which has a correspond-
ing asparagine in its active site [22], are consistent with
this explanation.
Conformational variability of the FBPase active
site
The three LmFBPase structures are compared with
corresponding mammalian FBPase structures in
Table 2. Co-crystallization of LmFBPase with F16BP,
magnesium, and potassium resulted in an apoenzyme
structure containing no substrate, product, or metals
and no observable electron density for the dynamic
loop (for two of the chains). This apoenzyme form ofuctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
Table 2. Comparisons of crystal structures of L. major and mammalian FBPases
Structure name LmFBPase
apoenzyme
plFBPase
apoenzyme
LmFBPase/
Mn/Pi
plFBPase/F6P/
Pi/Mg
LmFBPase/
F6P/AMP
plFBPase/F6P/Pi/
AMP/Mg
PDB code 5OEZ 2FBP 5OEY 1EYI 5OFU 1EYJ
Species/isoform L. major Pig liver L. major Pig liver L. major Pig liver
Space group P212121 P3221 P212121 I222 P212121 P21212
Topology Planar Planar Planar Planar Rotated Rotated
Ligand(s) in
crystallization drop
MgCl2, KCl,
F16BP
None MgCl2, MnCl2,
KCl, F16BP
MgCl2, F6P, KPi MgCl2, MnCl2,
KCl, F16BP, AMP
MgCl2, F6P, KPi,
AMP
Ligand(s) in structure None None Pi;
metal site 1: Mn;
metal site 2: Mn;
metal site 3:
unknown blob
F6P; Pi;
metal site 1: Mg;
metal site 2: Mg;
metal site 3:
unknown blob
F6P; AMP F6P; Pi;
metal site 1:
Mg; AMP
Dynamic loop Disordered Disordered Engaged Engaged Disengaged Disengaged
Reference This study Ke et al. [27] This study Choe et al. [33] This study Choe et al. [33]
9Leishmania Fructose-1,6-BisphosphataseLmFBPase is similar to the apoenzyme (R-state)
planar conformer of pig kidney FBPase (PDB code:
2FBP), where the dynamic loop is also completely
disordered [28].
The dynamic loop of LmFBPase was found to be
stabilized in an engaged conformation in the presence
of inorganic phosphate and manganese (Fig. 4b). This
corresponds to the observation that manganese
dramatically increases the thermostability of
LmFBPase (Fig. 3). The catalytic product Pi is found
in the active site, surrounded by two (or possibly three)
manganese atoms (Fig. 6d). In mammalian FBPase,
three divalent metal ions are required for hydrolysis of
F16BP [33]. Indeed, three electron density peaks were
found in each active site of this LmFBPase/Mn/Pi
structure; anomalous difference maps calculated from
data collected at 1.89 Å (the absorption edge for Mn)
showed clear peaks consistentwithmanganese ions at
metal sites I and II. The electron density at site III is only
slightly less than the electron density for the two
manganese ions; however, there is no observable
anomalous signal for site III, making potassium the
more likely candidate (Fig. 6d). This assignment is also
supported by the fact that potassium is required for
enzyme activity and is present at a concentration
100 mM in the enzyme assay conditions and was
present in the crystallization solution at 50 mM.
In the pig liver FBPase structure, an important water
molecule was found as a bridge between Asp74 and
metal II (Fig. 6c). This water molecule is presumed to
act as a catalytic base in the abstraction of a proton
from the second coordinated water molecule (coordi-
natedwithGlu98) [33]. Similar coordination geometries
around Mn-I and Mn-II are found in the LmFBPase
crystal structures with Mn–O distances close to 2.2 Å
[34]. Although Mn2+ was originally shown to act as a
cofactor for mammalian FBPase activity [35], here we
show that at higher concentrations Mn2+ is an inhibitor
of LmFBPase with a Ki ~45 μM (Fig. S2b).
In mammalian FBPases, a divalent metal ion is
retained at the metal site I in both R- and T-state
structures and remains coordinated with F6P and Pi,Please cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.as well as three acidic amino acids Asp118, Asp121,
and Glu280. In contrast, in the T-state structure of
LmFBPase/F6P/AMP, no metal atoms are found in
the active site. This rotated structure with a twist of
18° adopts a similar conformation to the rotated
conformation of pig liver FBPase (RMSD value of
0.85 Å), which has a twist of 15°.
Allosteric mechanism of LmFBPase
In mammalian FBPase structures, two canonical
structural states have been identified. The active state
structure (R-state) showed a planar tetramer confor-
mation, whereas a 15° rotation of the C1–C2 dimer
relative to the C3–C4 dimer was demonstrated to take
place in order to form the inactive state structure
(T-state) [12,31,33,36]. The structural superposition
between tetramer coordinates confirmed that the
apoenzyme structure of LmFBPase is more like the
active state (RMSD value of 1.1 Å) than the inactive
state (RMSD value of 3.7 Å) of pig liver FBPase.
In this study, both the apoenzyme structure of
LmFBPase and the complex structure with Pi and
manganese adopt planar conformations, whereas the
binding of AMP at the effector site induces an 18°
rotation along the small interface of the homotetramer
(animation shown in Supplementary Movie). As shown
in Fig. 5a, the conformational change from the planar
conformation (represented by black solid trapezoid
blocks) to the rotated conformation (represented by
purple dashed blocks) mainly takes place along the
short interface. In the planar structure (Fig. 5b, green),
with no AMP bound, the position of the effector loop
region between helices H1 and H2 is toward the C1–
C4 short interface. Within this loop, His23 makes a
hydrogen bond with the main-chain oxygen of Arg110
across the short interface and helps lock the interface
interaction in the planar R-state. When AMP binds to
the adjacent AMP binding pocket (shown in magenta),
the effector loop makes a large conformational change
and loop residueThr29 formsahydrogen bondwith the
adenine ring, while Arg25 forms a salt bridge with theuctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
10 Leishmania Fructose-1,6-Bisphosphatasephospho group. This effector loop movement breaks
the cross-interface interactions pulling the “His23-lock”
away from the interface. The unlocked chain (C4)
becomes free to rotate. This “unlock and rotate”
mechanism appears unique to the LmFBPase struc-
ture as there is little conservation of amino acid
sequence in the corresponding effector loops (residues
20–26) of the mammalian enzymes. In both liver and
muscle FBPase structures, helixH1 is extended byone
turn compared with LmFBPase in which Pro21 acts as
a helix breaker and serves to shorten the H1 helix,
thereby extending the effector loop (Fig. S4). This
proline is conserved inbothT. bruceiandTrypanosoma
cruzi sequences.
In the planar structures (Fig. 5c, green), the small
interface is stabilized by hydrogen bonds across the
small interface (including Gln14–Ser87, Glu198–
Thr37, Pro9–Tyr28). Upon AMP binding and dimer
rotation, these interactions are disrupted and a new
hydrogen bond Thr8–Ser87 is formed. These hydro-
gen bond changes across the small interface are also
coupled with the Arg48 conformational switch (de-
scribed above and in Fig. 5d), which ties the dynamic
loop in the “disengaged conformation” (Fig. 5d).
The residue corresponding to Arg48 in LmFBPase is
conserved in mammals and many other organisms
(e.g., E. coli and Schizosaccharomyces pombe,
shown in Fig. S5). Interestingly, in representatives of
all genera of the Kinetoplastea analyzed, whether
belonging to the trypanosomatid or bodonid families,
Arg is found, except in Trypanosoma (Fig. S5). In both
African and American trypanosomes, either Ser or Thr
is found at the position corresponding to LmArg48,
suggesting that a common ancestral species of the
genus Trypanosoma has lost Arg. Preliminary kinetic
analysis of T. brucei FBPase has shown that theFig. 7. Comparison of AMP binding sites. (a) Conformation o
PDB code: 3IFA). (b) Conformation of the AMP binding site in Lm
Fc maps contoured at the 3.0σ level.
Please cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.enzyme is much less sensitive to the AMP inhibitor,
with only 50% enzyme activity inhibition found at
0.8 mM AMP, at optimal substrate concentration. The
Arg mutation would explain this loss of sensitivity as
neither Ser nor Thr would be able to form a salt bridge
across the large interface and simultaneously lock
down the dynamic loop in the disengaged
conformation.
Structurally distinct effector site offers a drug
target against LmFBPase
Despite similarities in allosteric mechanisms of
Leishmania and mammalian FBPases, the AMP
allosteric binding sites show important differences
(Figs. 7 and S4). Zarzycki et al. [37] solved a human
FBPase crystal structure in complexwith AMP (Fig. 7a)
and showed that seven residues are responsible for the
binding of AMP. The notably different AMP binding site
in LmFBPase has six interacting residues (Fig. 7b), of
which only two (Tyr113 and Thr29) are conserved
suggesting their potential evolutionary importance. A
sequence alignment of 307 FBPases from different
organisms performed by Gao et al. showed the
conservation of these two residues.
The main difference in the AMP effector site is the
switch from Lys112 and Thr27 in hFBPase to Asp112
and Arg25 in LmFBPase (Fig. 7). This results is an
important change in the conformation of Arg140 which
interacts with the two hydroxyl groups of AMP in
hFBPase but forms a salt bridge with Asp112 in
LmFBPase and no longer binds with AMP, thereby
losing two direct hydrogen bonds with AMP, which is
consistent with its weaker binding (Table 1).
An FBPase null cell line of Leishmania major
showed a loss of ability to replicate in themacrophagef the AMP binding site in human muscle FBPase [37] (blue;
FBPase (green). The electron density shown is from Fo −
uctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
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infected mice [8]. These observations make
LmFBPase an interesting drug target for diseases
caused by Leishmania species.
Drugs targeting the AMP site of human FBPases
have been extensively studied and designed for the
treatment of type 2 diabetes. For instance, benzox-
azole benzenesulfonamides [38], imidazole analogues
[39], and some tricyclic compounds [40] have been
demonstrated to bind to the effector site of human liver
FBPases with affinities at the nanomolar level. Among
these human FBPase inhibitors, some of them (e.g.,
CS-917 under clinical phase 2b trials) have gained
particular success [41].
In this study, we showed that the Leishmania
FBPase effector site is structurally distinct from the
host FBPase isoforms and that the allosteric inhibition
mechanisms are also different. The structural differ-
ences at the effector site suggest that a species-
specific inhibitor could be developed. Evaluation of the
“druggability” of the effector pocket using a number of
prediction programs (Fig. S6) suggests that the effector
site ofLmFBPase is at least asdruggable as theproven
human target of liver FBPase.Materials and Methods
Gene cloning, overexpression, and protein
purification
The gene encoding L. major FBPase was amplified
by PCR using L. major (MHOM/SU/73/5-ASKH)
genomic DNA. The amplified fragments were ligated
into a pET24a vector (Novagen), which contains the
coding sequence for a C-terminal His6 tag. The
overexpression plasmid was used to transform E. coli
BL21(DE3) Gold strain (Novagen). Single colonies
were picked from LB kanamycin (50 μg/ml) plates and
used to inoculate 50 ml of LB medium (containing
kanamycin). Cultures were grown overnight at 37 °C
and 250 rpm. Aliquots (10 ml) were used to inoculate
500 ml of LB medium (containing kanamycin) in 2-L
Erlenmeyer flasks. The cell culture was grown at 37 °C
and 250 rpm to an OD600 of 1.0, at which time
LmFBPase expression was induced by the addition
of isopropyl-β-D-thiogalactopyranoside (final concen-
tration 1 mM). The culture was maintained (at 30 °C
and 120 rpm) for an additional 24 h. The cells were
then harvested, followed by lysing with a constant cell
disruption system in lysis buffer [50 mM triethanola-
mine (TEA), 300 mM NaCl, 20 mM imidazole, and 1
tablet EDTA-free protease inhibitors (Roche), pH 8.0]
at 25 MPa. The lysate was centrifuged at 6 °C for
45 min at 60,000g, and the supernatant was filtered
through a 0.2-μm syringe filter. The C-terminal-His6-
LmFBPase was purified from lysates using immobi-
lized metal ion affinity chromatography on a nickelPlease cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.affinity resin (GE Healthcare Co., Ltd.), followed by a
size-exclusion step with a HiPrep 16/60 S200 column
(GE Healthcare Co., Ltd.). Purified protein was
concentrated to 5 mg/ml using a centrifugal membrane
concentrator (Sartorius Co., Ltd.), and then frozen in
liquid nitrogen and stored at −80 °C.
Enzyme activity assays
PGI and G6PDHwere used as coupling enzymes in
assays for LmFBPase. For the determination of its
specific activity with the substrate F16BP, reduction of
NADP+ to NADPH was monitored by absorbance at
340 nm. For the determination of kinetic parameters of
LmFBPase, enzyme activity assays were performed
as follows. Fifty microliters of different concentrations
of F16BP (from 0 to 500 μM) in assay buffer [50 mM
TEA, 100 mM KCl, 10 mM MgCl2, 5% glycerol
(pH 8.0)] were added into each well in a 96-well
microtiter plate. Fifty microliters of solution containing
4.6 μg/ml of LmFBPase, 1.4 U/ml of PGI, 0.8 U/ml of
G6PDH, and 0.5 mM of NADP+ in the same assay
buffer were added to each well to start the reaction.
The increase in absorbance at 340 nm (the absor-
bance of NADPH) was measured for 5 min at 37 °C
using a plate reader. The kinetic parameters (Vmax,
K0.5(F16BP), and nH) were determined by curve fitting to
the data with the equation below.
V ¼ Vmax  F16BP½ 
nH
K 0:5
nH þ F16BP½ nH
For the determination of the effects of AMP and
manganese on LmFBPase activity, 50 μl of different
concentrations of AMP or MnCl2 (from 0 to 2 mM) in
assay buffer in the presence of a sub-saturating
concentration of F16BP (40 μM) was added to each
well. After 50 μl of mixed solution containing 4.6 μg/ml
of LmFBPase, 1.4 U/ml of PGI, 0.8 U/ml of G6PDH,
and 0.5 mM of NADP+ in the same assay buffer were
added to each well to start the reaction, the enzyme
activities were assayed at 37 °C. The activation
effects of magnesium were also determined using
similar methods but at a saturating concentration
(250 μM) of F16BP.
TDA
A fluorescence-based TDA was performed to
characterize the thermal stability of LmFBPase with a
Bio-Rad iQ5 rtPCR Thermocycler [42]. Each sample
contained 0.1 mg/ml of the enzyme, 5× SYPRO
orange (original 5000× stock from Life Technologies
Co., Ltd.), and 2 mM of each ligand (and/or 10 mM of
MnCl2) in 50 μl of 1× buffer [10 mM MgCl2, 100 mM
KCl, 50 mM TEA, 10% glycerol (pH 7.2)]. The 96-well
plate containing the samples was heated at rate of
1.0 °C/min from 20 to 80 °C, and the fluorescence
intensity was measured with excitation/emissionuctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
org/10.1016/j.jmb.2017.08.010
12 Leishmania Fructose-1,6-Bisphosphatasewavelengths of 490 and 580 nm, respectively. Melting
temperature (Tm) values were calculated by the
software CFX Manager. Samples were tested in
duplicate.
Protein crystallization and data collection
Single crystals of LmFBPasewere obtained by vapor
diffusion using the hanging-drop technique. (1) The
crystals of the apoenzyme structure were formed by
mixing 1.5 μl of LmFBPase (3.8 mg/ml of enzyme in
20 mM TEA, 5 mM MgCl2, 50 mM KCl, 10% glycerol,
1 mM F16BP, pH 7.0 solution) with 1.5 μl reservoir
solution [20%w/vPEG3350 (0.05 Mcitric acid, 0.05 M
Bis–Tris propane, pH 5.0)] and “silver bullet 85” [43] in
crystal growth kit HR2-096 from Hampton Research
Co., Ltd. [19 amino acids excluding cysteine in 0.02 M
sodium Hepes (pH 6.8)]. The crystals were grown at
17 °C.Plate-like crystals appearedafter 3 days. (2) The
crystals of LmFBPase/Mn2+/Pi were crystallized by
mixing 1.5 μl of LmFBPase [4.0 mg/ml of enzyme in
20 mM TEA, 5 mM MgCl2, 50 mM KCl, 10% glycerol,
1 mM F16BP, and 10 mMMnCl2, (pH 7.0)] with 1.5 μl
reservoir solution [20% w/v PEG 3350 (0.05 M citricTable 3. Crystallographic data collection and model refinemen
LmFBPase apo-structure
PDB code 5OEZ 5OE
Wavelength 0.9795 0.97
Resolutiona (Å) 58.77–2.41 (2.496–2.41) 55.1
Space group P212121 P21
Unit cell a,b,c (Å) 55.26, 162.56, 170.13 92.0
Total reflections 290,741 (22,595) 457
Unique reflections 59,755 (5885) 33,2
Multiplicity 4.9 (5.2) 13.7
Completeness (%) 99.4 (99.8) 100
Mean I/sigma(I) 9.2 (2.9) 12.3
Wilson B-factor 50.2 26.5
Rmerge
b (%) 9.4 (86.1) 5.4
Rwork
c 0.187 0.19
Rfree
d 0.225 0.24
Number of non-hydrogen atoms 9880 10,1
Macromolecules 9755
(4 × macromolecules)
992
(4 ×
Waters 125 141
Ligands none 54 (
Protein residues 1244 128
RMS (bonds, Å) 0.01 0.01
RMS (angles, °) 1.416 1.4
Ramachandran favored (%) 98 97
Ramachandran allowed (%) 2 3
Ramachandran outliers (%) 0 0.1
Rotamer outliers (%) 4 5
Clashscore 3 4
Average B-factor 66.10 33.5
Macromolecules 66.27 33.6
Ligands N/A 50.0
Solvent 52.28 15.2
a Values in parentheses are for the highest resolution shell.
b Rmerge = Ʃhkl | I − b IN|/ƩhklI.
c Rwork = Ʃ |Fobs − Fcalc |/Ʃ |Fobs |, where Fobs and Fcalc are the obse
d Rfree is calculated using 5% of total reflections randomly chosen a
Please cite this article as: M. Yuan, et al., Structures of Leishmania Fr
the Mechanism of Allosteric Inhibition, J. Mol. Biol. (2017), http://dx.doi.acid, 0.05 M Bis–Tris propane, pH 6.0)]. Crystals were
grown in 3weeks at 17 °C. Twenty percent of PEG400
plus 10% glycerol were used as cryoprotectants. (3)
For the crystals of LmFBPase/F6P/AMP, 1.5 μl of
LmFBPase [3.4 mg/ml of enzyme in 20 mM TEA,
5 mMMgCl2, 50 mMKCl, 10%glycerol, 1 mMF16BP,
10 mM MnCl2 and 2 mM AMP (pH 7.2)] was mixed
with 1.5 μl reservoir solution [19% w/v PEG 3350
(0.05 M citric acid, 0.05 M Bis–Tris propane, pH 6.0)].
Crystals were grown for 4 weeks at 4 °C. The X-ray
data sets were collected on Beamline I02 (for the
apoenzyme structure), Beamline I04 (for the structure
of LmFBPase/Mn2+/Pi), and Beamline I03 (for the
structure of LmFBPase/F6P/AMP) at the Diamond
synchrotron radiation facility in Oxfordshire, United
Kingdom. Each data set was obtained from a
single-crystal flash-frozen in liquid nitrogen.
Structure determination
The data of the apoenzyme structure were
processed with xia2 [44]. The structure was solved
with molecular replacement against pig liver FBPase
(PDB code: 5FBP) [31] using the program PHASERt statistics.
LmFBPase + Mn2++Pi LmFBPase + F6P + AMP
Y 5OFU
95 0.9700
4–2.8 (2.9–2.8) 70.25–2.62 (2.714–2.62)
2121 P212121
1, 104.15, 137.74 90.59 109.25 140.51
,591 (67,605) 232,518 (16,569)
15 (3280) 42,513 (4158)
(14.1) 5.5 (5.4)
(100) 99.9 (99.6)
(3.5) 12.4 (2.1)
45.3
(74.1) 10.2 (77.3)
8 0.188
4 0.216
20 10,279
5
macromolecules)
10,007
(4 × macromolecules)
114
4 × PO4, 12 × Mn
2+, 2 × Cit) 158 (4 × F6P, 4 × AMP, 2 × Cl)
7 1282
0.009
1.416
97
3
0
3
2
1 56.20
7 57.46
0 49.00
5 42.36
rved and the calculated structure factors, respectively.
nd excluded from the refinement.
uctose-1,6-Bisphosphatase Reveal Species-Specific Differences in
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13Leishmania Fructose-1,6-Bisphosphatase[45] and the sequence of LmFBPase in Autobuild
[46]. The initial models were subjected to a cycle of
rigid-body refinement followed by several cycles of
restrained refinement using the program REFMAC
[47]. The models were then manually adjusted using
COOT [48], followed by several cycles of restrained
refinement (without NCS restraints) using REFMAC
or PHENIX [49]. Water molecules were manually
added to the structure using COOT. After additional
cycles of restrained refinement and manual adjust-
ments to side chains and water molecules, the
overall quality of the map improved. Missing loops
were then built up manually using COOT followed by
cycles of translation libration screw (TLS) refinement
[50] and restrained refinement in REFMAC and
COOT adjustments. TLS groups were generated
according to the domain region of LmFBPase for
each chain using TLS Motion Determination. The
first seven TLS groups were used for each structure.
The data of LmFBPase with bound manganese and
phosphate ions were processed with MOSFLM [51]
and scaled with SCALA [52]. This structure was solved
using the coordinates of one monomer from the
apoenzyme structure. Briefly, all four subunits were
found using the program PHASER, and this initial
modelwas thenmodifiedwith cycles ofmanual building
with COOT and restrained refinement as described
above with the apoenzyme structure. When appropri-
ate, relevant ligandmolecules were added where clear
unbiasedFo−Fc electron densitywas observed.Water
molecules were added to the model using COOT, and
after several rounds of restrained refinement, the R/
Rfree values converged.
The data of LmFBPase with bound F6P and AMP
were processed with xia2 [44]. This structure was
solved using the coordinates of onemonomer from the
apoenzyme structure. Like the two solved structures
above, four subunits were found in each asymmetric
unit. Molecular replacement and structure refinement
were performed with PHASER, REFMAC, andCOOT.
Data collection and refinement statistics are summa-
rized in Table 3. Pair-rotation angles were measured
with the Cα atoms of Ala128 and Asp144 between the
planar and rotated structures.
The molecular interface area is calculated as the
difference in total accessible surface areas of
isolated and interfacing structures divided by two
(calculated with the program PDBePISA [53]).
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.jmb.2017.08.010.Acknowledgments
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